as 12-17-2024 4:00pm EST
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Founded: | 2000 | Country: | Germany |
Employees: | N/A | City: | N/A |
Market Cap: | 637.1M | IPO Year: | 2020 |
Target Price: | $10.00 | AVG Volume (30 days): | 523.1K |
Analyst Decision: | Hold | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.33 | EPS Growth: | N/A |
52 Week Low/High: | $2.21 - $5.28 | Next Earning Date: | 11-12-2024 |
Revenue: | $70,565,734 | Revenue Growth: | 75.11% |
Revenue Growth (this year): | 738.59% | Revenue Growth (next year): | -87.39% |
CVAC Breaking Stock News: Dive into CVAC Ticker-Specific Updates for Smart Investing
Simply Wall St.
20 days ago
Simply Wall St.
22 days ago
Zacks
a month ago
Insider Monkey
a month ago
Pharma Voice
a month ago
GuruFocus.com
a month ago
ACCESSWIRE
a month ago
ACCESSWIRE
a month ago
The information presented on this page, "CVAC CureVac N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.